Skip navigation
Home
Browse
Communities
& Collections
Browse Items by:
Issue Date
Author
Title
Advisor
Help
Sign on to:
My DSpace
Receive email
updates
Edit Profile
Adelaide Research & Scholarship
Adelaide Research & Scholarship
Search
Search:
All collections
Schools and Disciplines
School of Medicine
Anaesthesia and Intensive Care
Medicine
Opthalmology & Visual Sciences
Orthopaedics and Trauma
Psychiatry
Surgery
for
Current filters:
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Start a new search
Add filters:
Use filters to refine the search results.
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Results 11-20 of 38 (Search time: 0.002 seconds).
previous
1
2
3
4
next
Item hits:
Preview
Issue Date
Title
Author(s)
2013
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase
Hochhaus, A.
;
Saglio, G.
;
Larson, R.
;
Kim, D.
;
Etienne, G.
;
Rosti, G.
;
De Souza, C.
;
Kurokawa, M.
;
Kalaycio, M.
;
Hoenekopp, A.
;
Fan, X.
;
Shou, Y.
;
Kantarjian, H.
;
Hughes, T.
2013
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Baccarani, M.
;
Deininger, M.
;
Rosti, G.
;
Hochhaus, A.
;
Soverini, S.
;
Apperley, J.
;
Cervantes, F.
;
Clark, R.
;
Cortes, J.
;
Guilhot, F.
;
Hansen-Hjorth, H.
;
Hughes, T.
;
Kantarjian, H.
;
Kim, D.
;
Larson, R.
;
Lipton, J.
;
Mahon, F.
;
Martinelli, G.
;
Mayer, J.
;
Muller, M.
;
et al.
2013
Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy
Angelini, S.
;
Soverini, S.
;
Ravegnini, G.
;
Barnett, M.
;
Turrini, E.
;
Thornquist, M.
;
Pane, F.
;
Hughes, T.
;
White, D.
;
Radich, J.
;
Kim, D.
;
Saglio, G.
;
Cilloni, D.
;
Iacobucci, I.
;
Perini, G.
;
Woodman, R.
;
Cantelli-Forti, G.
;
Baccarani, M.
;
Hrelia, P.
;
Martinelli, G.
2012
Drug-interaction studies evaluating T-cell proliferation reveal distinct activity of dasatinib and imatinib in combination with cyclosporine A
Blake, S.
;
Hughes, T.
;
Lyons, A.
2013
Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells
White, D.
;
Eadie, L.
;
Saunders, V.
;
Hiwase, D.
;
Hughes, T.
2010
Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy
Hiwase, D.
;
White, D.
;
Zrim, S.
;
Saunders, V.
;
Vaz de Melo, J.
;
Hughes, T.
2011
OCT-1 as a determinant of response to antileukemic treatment
Engler, J.
;
Hughes, T.
;
White, D.
2011
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial
Kantarjian, H.
;
Hochhaus, A.
;
Saglio, G.
;
de Souza, C.
;
Flinn, I.
;
Stenke, L.
;
Goh, Y.
;
Rosti, G.
;
Nakamae, H.
;
Gallagher, N.
;
Hoenekopp, A.
;
Blakesley, R.
;
Larson, R.
;
Hughes, T.
2010
Practical considerations for monitoring patients with chronic myeloid leukemia
Branford, S.
;
Hughes, T.
2010
Nilotinib versus Imatinib for newly diagnosed chronic myeloid leukemia
Saglio, G.
;
Kim, D.
;
Issaragrisil, S.
;
le Coutre, P.
;
Etienne, G.
;
Lobo, C.
;
Pasquini, R.
;
Clark, R.
;
Hochhaus, A.
;
Hughes, T.
;
Gallagher, N.
;
Hoenekopp, A.
;
Haque, A.
;
Dong, M.
;
Larson, R.
;
Kantarjian, H.
Discover
Author
16
White, D.
12
Branford, S.
11
Hochhaus, A.
10
Kantarjian, H.
8
Larson, R.
8
Saglio, G.
7
Kim, D.
6
Radich, J.
5
Cortes, J.
5
Guilhot, F.
.
next >
Subject
34
Humans
31
Piperazines
30
Benzamides
27
Imatinib Mesylate
26
Leukemia, Myelogenous, Chronic, B...
25
Antineoplastic Agents
24
Protein Kinase Inhibitors
14
Fusion Proteins, bcr-abl
12
Female
12
Male
.
next >
Date issued
2
2017
6
2014
10
2013
3
2012
7
2011
10
2010